Accutar Biotechnology Announces FDA Clearance of IND Application for Phase I Trial of AC0682 in ER-Positive Breast Cancer

Accutar Biotechnology, Inc. announced that the FDA has cleared the company’s investigational new drug application (IND) for AC0682 for the treatment of patients with estrogen receptor (ER)-positive breast cancers.